News
Immunitybio Announces Results Of Anktiva Combined With Checkpoint Inhibitors In Non-Small Cell Lung Cancer; Schedules Meeting To Discuss Registration Path For ANKTIVA In Lung Cancer With FDA
25 Apr 24
News
FDA Approves ImmunityBio's Bladder Cancer Drug, Stock Rallies
23 Apr 24
Biotech, News, Health Care, FDA, Top Stories, Movers, General
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
23 Apr 24
Movers
Why Hibbett Shares Are Trading Higher By 18%; Here Are 20 Stocks Moving Premarket
23 Apr 24
News, Pre-Market Outlook, Markets, Movers
Reported Earlier, ImmunityBio Has Received FDA Approval For ANKTIVA, A First-In-Class IL-15 Receptor Agonist, For BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
23 Apr 24
News
Piper Sandler Maintains Neutral on ImmunityBio, Raises Price Target to $5
25 Mar 24
News, Price Target, Analyst Ratings
10 Health Care Stocks With Whale Alerts In Today's Session
20 Mar 24
Options
Sportradar Group Posts Upbeat Earnings, Joins Kingsoft Cloud, Braskem And Other Big Stocks Moving Higher On Wednesday
20 Mar 24
News, Penny Stocks, Small Cap, Intraday Update, Markets, Movers, Trading Ideas
ImmunityBio: Q4 Earnings Insights
19 Mar 24
Earnings
Immunitybio Announced Data From Phase 1 Pilot Study Showed N-803 Combined With Natural Killer Cells Could Reduce Viral Load In People Living With HIV
5 Mar 24
Biotech, General
Why Freshpet Shares Are Trading Higher By Around 15%? Here Are Other Stocks Moving In Monday's Mid-Day Session
26 Feb 24
News, Penny Stocks, Small Cap, Intraday Update, Markets, Movers, Trading Ideas
10 Health Care Stocks With Whale Alerts In Today's Session
26 Feb 24
Options
Why Intuitive Machines Shares Are Trading Lower By Around 30%; Here Are 20 Stocks Moving Premarket
26 Feb 24
News, Penny Stocks, Pre-Market Outlook, Markets, Movers, Trading Ideas
12 Health Care Stocks Moving In Monday's Pre-Market Session
26 Feb 24
Movers
Why MercadoLibre Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session
23 Feb 24
Earnings, News, Penny Stocks, Small Cap, Intraday Update, Markets, Movers, Trading Ideas
12 Health Care Stocks Moving In Friday's Intraday Session
23 Feb 24
Movers
ImmunityBio Announces Full Accrual Of First Two Phases Of Cancer Vaccine Trial In Participants With Lynch Syndrome And Initiation Of Randomized Controlled Phase Of The Trial
21 Feb 24
Biotech, News, General
ImmunityBio Quality-Of-Life Study In BCG-Unresponsive Bladder Cancer Trial Indicates Improved Physical Function In The 71% Complete Responders Suggesting A Favorable Risk-Benefit Ratio For N-803 Plus BCG
5 Feb 24
Biotech, News, FDA, General
Press releases
ImmunityBio Announces Positive Overall Survival Results of Anktiva Combined With Checkpoint Inhibitors in Non-Small Cell Lung Cancer; Meeting Scheduled with FDA to Discuss Registration Path for ANKTIVA in Lung Cancer
25 Apr 24
Press Releases
ImmunityBio Announces FDA Approval of ANKTIVA®, First-in-Class IL-15 Receptor Agonist for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
22 Apr 24
Press Releases
Biotech's Role in Addressing the Pancreatic Cancer Emergency
14 Mar 24
Small Cap, Opinion, Press Releases
NIAID-Sponsored Study Shows N-803 Combined with Neutralizing Antibodies Could Lead to Sustained HIV Viral Control After Discontinuation of Antiretroviral Therapy
6 Mar 24
Press Releases
N-803 Combined with Natural Killer Cells Showed Potential to Reduce HIV Viral Load in HIV Positive Subjects; Part of HIV Cure Study
5 Mar 24
Press Releases
Biotech With Potential: Coeptis Therapeutics (COEP) And 3 Underrated Gems
21 Feb 24
ImmunityBio Announces Full Accrual of First Two Phases of Cancer Vaccine Trial in Participants with Lynch Syndrome and Initiation of Randomized Controlled Phase of the Trial
21 Feb 24
Press Releases
Bladder cancer Pipeline Assessment 2024: FDA Approvals, Clinical Trials, Therapies and Companies by DelveInsight | Aura Biosciences, BeiGene, Incyte, CG Oncology, FKD Therapies
15 Feb 24
News, Press Releases
ImmunityBio Quality-of-Life Study in BCG-Unresponsive Bladder Cancer Trial Indicates Improved Physical Function in the 71% Complete Responders Suggesting a Favorable Risk-Benefit Ratio for N-803 Plus BCG
5 Feb 24
Press Releases